Role of MicroRNAs in NAFLD/NASH

被引:74
|
作者
Szabo, Gyongyi [1 ]
Csak, Timea [1 ,2 ]
机构
[1] Univ Massachusetts, Sch Med, Dept Med, LRB215,364 Plantat St, Worcester, MA 01605 USA
[2] Brookdale Univ Hosp & Med Ctr, 1 Brookdale Plaza, Brooklyn, NY 11212 USA
关键词
MicroRNAs; NASH; NAFLD; FATTY LIVER-DISEASE; OBSTRUCTIVE SLEEP-APNEA; NONALCOHOLIC STEATOHEPATITIS; ADIPOSE-TISSUE; CIRCULATING MICRORNAS; METABOLIC SYNDROME; URIC-ACID; GUT MICROBIOTA; HEPATOCELLULAR-CARCINOMA; DIFFERENTIAL EXPRESSION;
D O I
10.1007/s10620-015-4002-4
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
MicroRNAs (miRNAs) are highly conserved, small, 18-25 nucleotide, non-coding RNAs that regulate gene expression at the post-transcriptional level. Each miRNA can regulate hundreds of target genes, and vice versa each target gene can be regulated by numerous miRNAs, suggesting a very complex network and explaining how miRNAs play pivotal roles in fine-tuning essentially all biological processes in all cell types in the liver. Here, we summarize the current knowledge on the role of miRNAs in the pathogenesis and diagnosis of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) with an outlook to the broader aspects of metabolic syndrome. Furthermore, we discuss the role of miRNAs as potential biomarkers and therapeutic targets in NAFLD/NASH.
引用
收藏
页码:1314 / 1324
页数:11
相关论文
共 50 条
  • [31] Pathophysiology of NAFLD and NASH in Experimental Models: The Role of Food Intake Regulating Peptides
    Korinkova, L.
    Prazienkova, V
    Cerna, L.
    Karnosova, A.
    Zelezna, B.
    Kunes, J.
    Maletinska, Lenka
    FRONTIERS IN ENDOCRINOLOGY, 2020, 11
  • [32] A pivotal year for NAFLD and NASH therapeutics
    Dufour, Jean-Francois
    NATURE REVIEWS ENDOCRINOLOGY, 2024, 20 (02) : 75 - 76
  • [33] PREVENTION AND PHARMACOLOGICAL INTERVENTIONS IN NAFLD/NASH
    De Block, C.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2020, 22 : A13 - A13
  • [34] Current medical treatment for NAFLD/NASH
    Masrour, Oumnia
    Bardou-Jacquet, Edouard
    NUTRITION CLINIQUE ET METABOLISME, 2023, 37 (02): : 72 - 76
  • [35] Innate Immunity and Inflammation in NAFLD/NASH
    Arrese, Marco
    Cabrera, Daniel
    Kalergis, Alexis M.
    Feldstein, Ariel E.
    DIGESTIVE DISEASES AND SCIENCES, 2016, 61 (05) : 1294 - 1303
  • [36] A pivotal year for NAFLD and NASH therapeutics
    Jean-François Dufour
    Nature Reviews Endocrinology, 2024, 20 : 75 - 76
  • [37] Predicting NASH in NAFLD without a Biopsy
    Klein, Friederike
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2021, 59 (07):
  • [38] Predicting the future burden of NAFLD and NASH
    Mahady, Suzanne E.
    George, Jacob
    JOURNAL OF HEPATOLOGY, 2018, 69 (04) : 774 - 775
  • [39] Imaging biomarkers of NAFLD, NASH, and fibrosis
    Ajmera, Veeral
    Loomba, Rohit
    MOLECULAR METABOLISM, 2020, 50
  • [40] Prevention of NAFLD/NASH by Astaxanthin and β-Cryptoxanthin
    Ota, Tsuguhito
    CAROTENOIDS: BIOSYNTHETIC AND BIOFUNCTIONAL APPROACHES, 2021, 1261 : 231 - 238